Terms: = Kidney tumors AND TFRC, P02786, 7037, ENSG00000072274, TFR1, CD71
12 results:
1. Identification and validation of a ferroptosis-related signature for prediction of the prognosis and tumor microenvironment in patients with chromophobe renal cell carcinoma.
Liu S; Yao Y; Hou M; Mei J; Sun L; Zhang G
BMC Cancer; 2023 Nov; 23(1):1079. PubMed ID: 37940859
[TBL] [Abstract] [Full Text] [Related]
2. Anemia, Iron Deficiency, and Iron Regulators in Pancreatic Ductal Adenocarcinoma Patients: A Comprehensive Analysis.
Osmola M; Gierej B; Mleczko-Sanecka K; Jończy A; Ciepiela O; Kraj L; Ziarkiewicz-Wróblewska B; Basak GW
Curr Oncol; 2023 Aug; 30(8):7722-7739. PubMed ID: 37623041
[TBL] [Abstract] [Full Text] [Related]
3. Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics.
Lucaroni L; Georgiev T; Prodi E; Puglioli S; Pellegrino C; Favalli N; Prati L; Manz MG; Cazzamalli S; Neri D; Oehler S; Bassi G
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):957-961. PubMed ID: 36184692
[TBL] [Abstract] [Full Text] [Related]
4. Identification of appropriate housekeeping genes for gene expression studies in human renal cell carcinoma under hypoxic conditions.
Teixeira LFS; Gigliotti R; da Silva Ferreira L; Bellini MH
Mol Biol Rep; 2022 May; 49(5):3885-3891. PubMed ID: 35277789
[TBL] [Abstract] [Full Text] [Related]
5. Characteristics and prognostic value of potential dependency genes in clear cell renal cell carcinoma based on a large-scale CRISPR-Cas9 and RNAi screening database DepMap.
Shi B; Ding J; Qi J; Gu Z
Int J Med Sci; 2021; 18(9):2063-2075. PubMed ID: 33850477
[TBL] [Abstract] [Full Text] [Related]
6. Association of Damaging Variants in Genes With Increased Cancer Risk Among Patients With Congenital Heart Disease.
Morton SU; Shimamura A; Newburger PE; Opotowsky AR; Quiat D; Pereira AC; Jin SC; Gurvitz M; Brueckner M; Chung WK; Shen Y; Bernstein D; Gelb BD; Giardini A; Goldmuntz E; Kim RW; Lifton RP; Porter GA; Srivastava D; Tristani-Firouzi M; Newburger JW; Seidman JG; Seidman CE
JAMA Cardiol; 2021 Apr; 6(4):457-462. PubMed ID: 33084842
[TBL] [Abstract] [Full Text] [Related]
7. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.
Jeong DE; Song HJ; Lim S; Lee SJ; Lim JE; Nam DH; Joo KM; Jeong BC; Jeon SS; Choi HY; Lee HW
Oncotarget; 2015 Oct; 6(32):33046-64. PubMed ID: 26426994
[TBL] [Abstract] [Full Text] [Related]
8. MicroRNA target site polymorphisms in the VHL-HIF1α pathway predict renal cell carcinoma risk.
Wei H; Ke HL; Lin J; Shete S; Wood CG; Hildebrandt MA
Mol Carcinog; 2014 Jan; 53(1):1-7. PubMed ID: 22517515
[TBL] [Abstract] [Full Text] [Related]
9. Examination of the distribution of the transferrin homologue, melanotransferrin (tumour antigen p97), in mouse and human.
Sekyere EO; Dunn LL; Richardson DR
Biochim Biophys Acta; 2005 Mar; 1722(2):131-42. PubMed ID: 15716025
[TBL] [Abstract] [Full Text] [Related]
10. Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes.
Grünebach F; Müller MR; Nencioni A; Brossart P
Gene Ther; 2003 Mar; 10(5):367-74. PubMed ID: 12601391
[TBL] [Abstract] [Full Text] [Related]
11. Effect of granulocyte-macrophage colony-stimulating factor treatment on phenotype, cytokine release and cytotoxicity of circulating blood monocytes and monocyte-derived macrophages.
Hennemann B; Kreutz M; Rehm A; Andreesen R
Br J Haematol; 1998 Sep; 102(5):1197-203. PubMed ID: 9753045
[TBL] [Abstract] [Full Text] [Related]
12. Analysis of T-cell immune response in renal cell carcinoma: polarization to type 1-like differentiation pattern, clonal T-cell expansion and tumor-specific cytotoxicity.
Angevin E; Kremer F; Gaudin C; Hercend T; Triebel F
Int J Cancer; 1997 Jul; 72(3):431-40. PubMed ID: 9247286
[TBL] [Abstract] [Full Text] [Related]
